Bariatric Surgery Long-Term Outcomes

Bariatric surgery evolved from experimental jejunoileal bypass in the 1960s through gastric banding to Roux-en-Y gastric bypass (RYGB). While effective for weight loss, the long-term metabolic and mortality benefits remained unproven for decades. The Swedish Obese Subjects (SOS) study — a prospective, matched cohort enrolling 4,047 patients — provided the first evidence of long-term mortality reduction.

STAMPEDE (2012) provided the strongest evidence for bariatric surgery as metabolic therapy. In 150 patients with type 2 diabetes and BMI 27-43, surgical treatment (RYGB or sleeve gastrectomy) was dramatically superior to intensive medical therapy for glycaemic control: 42% (RYGB) and 37% (sleeve) achieved HbA1c <6.0% at 1 year versus just 12% with medical therapy alone. The 5-year follow-up (2017) confirmed sustained benefit, establishing the concept of 'metabolic surgery' as a therapeutic intervention for diabetes rather than merely a weight-loss procedure.

The American Diabetes Association 2022 Standards of Care endorsed metabolic surgery as a treatment option for type 2 diabetes in patients with BMI ≥35 (Class I recommendation), with consideration for BMI 30-35 (Class II). IFSO and ASMBS broadened eligibility criteria, recognising that BMI thresholds alone are insufficient for patient selection.

Bariatric/metabolic surgery is firmly established as the most effective long-term treatment for severe obesity and its metabolic complications. Sleeve gastrectomy has overtaken RYGB as the most commonly performed procedure globally. GLP-1 receptor agonists (semaglutide, tirzepatide) are challenging surgery's dominance for weight loss, prompting ongoing trials comparing pharmacotherapy to surgery. The field increasingly emphasises metabolic outcomes over weight loss alone.